Cargando…

Targeting the entry step of SARS-CoV-2: a promising therapeutic approach

Detalles Bibliográficos
Autores principales:	Li, Jing, Zhan, Peng, Liu, Xinyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298436/ https://www.ncbi.nlm.nih.gov/pubmed/32555145 http://dx.doi.org/10.1038/s41392-020-0195-x

Ejemplares similares

A two‐step infection model: From SARS‐CoV‐2 entry and trafficking to egress and spread
por: You, Liting, et al.
Publicado: (2023)

Opsonizing antibodies mediated SARS‐CoV‐2 entry into monocytes leads to inflammation
por: Yao, Tong, et al.
Publicado: (2022)

Kidney injury molecule-1: a novel entry factor for SARS-CoV-2
por: Wan, Cheng, et al.
Publicado: (2021)

Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
por: Solimani, Farzan, et al.
Publicado: (2021)

Promising inhibitors targeting M(pro): an ideal strategy for anti-SARS-CoV-2 drug discovery
por: Chen, Yi, et al.
Publicado: (2020)

SARS-CoV-2-induced lung pathology: AHR as a candidate therapeutic target
por: Giovannoni, Federico, et al.
Publicado: (2020)

Super(antigen) target for SARS-CoV-2
por: Brown, Matthew, et al.
Publicado: (2021)

SMIP-30, a potent and selective PPM1A inhibitor with potential to treat tuberculosis
por: Xu, Shujing, et al.
Publicado: (2022)

A promising strategy against SARS-CoV-2: pyrimidine inhibitors synergize with nucleoside analogues
por: Min, Long, et al.
Publicado: (2022)

A promiscuous interaction of SARS-CoV-2 with bacterial products
por: Carissimo, Guillaume, et al.
Publicado: (2020)

Virtual Issue on SARS-CoV-2: Evolution of a Pandemic
por: McGrath, Casey
Publicado: (2023)

SARS-CoV-2: the many pros of targeting PLpro
por: McClain, Christopher B., et al.
Publicado: (2020)

Autoimmunity and SARS‐CoV‐2 infection: Unraveling the link in neurological disorders
por: Latorre, Daniela
Publicado: (2022)

Induction of membraneless organelles as a strategy for HIV-1 post-nuclear entry steps
por: Zhou, Sheng, et al.
Publicado: (2023)

Circular RNA vaccine, a novel mRNA vaccine design strategy for SARS‐CoV‐2 and variants
por: Su, Peng, et al.
Publicado: (2022)

Not only ACE2—the quest for additional host cell mediators of SARS-CoV-2 infection: Neuropilin-1 (NRP1) as a novel SARS-CoV-2 host cell entry mediator implicated in COVID-19
por: Kyrou, Ioannis, et al.
Publicado: (2021)

Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
por: Wang, Qiao, et al.
Publicado: (2023)

In search for novel strategies towards neuroprotection and neuroregeneration: is PPARα a promising therapeutic target?
por: Moreno, Sandra, et al.
Publicado: (2015)

SARS-CoV-2 sensory loss
por: York, Ashley
Publicado: (2022)

Sewer biofilms and SARS-CoV-2
por: Du Toit, Andrea
Publicado: (2023)

SURFing SARS-CoV-2 inhibition
por: Taglialegna, Agustina
Publicado: (2023)

A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virus
por: Wang, Junzhi
Publicado: (2021)

SARS-CoV-2 spike protein: flexibility as a new target for fighting infection
por: Pierri, Ciro Leonardo
Publicado: (2020)

A CNS gateway for SARS-CoV-2
por: Yates, Darran
Publicado: (2021)

SARS-CoV-2 detected in olfactory neurons
por: Lemprière, Sarah
Publicado: (2021)

Cellular basis for SARS-CoV-2 infection
por: Baumann, Kim
Publicado: (2020)

Timing vaccination against SARS-CoV-2
por: Barnoud, Coline, et al.
Publicado: (2021)

SARS-CoV-2 nanobodies 2.0
por: Labroussaa, Fabien, et al.
Publicado: (2021)

Effects of mutations on SARS-CoV-2 fitness
por: Chirigati, Fernando
Publicado: (2022)

SARS-CoV-2 rewires host chromatin
por: Du Toit, Andrea
Publicado: (2023)

Antigen‐dependent multistep differentiation of T follicular helper cells and its role in SARS‐CoV‐2 infection and vaccination
por: Baumjohann, Dirk, et al.
Publicado: (2021)

Type I interferon signaling deficiency results in dysregulated innate immune responses to SARS‐CoV‐2 in mice
por: Ogger, Patricia P., et al.
Publicado: (2022)

Landscapes of SARS-CoV-2-reactive CD8(+) T cells: heterogeneity of host immune responses against SARS-CoV-2
por: Koh, June-Young, et al.
Publicado: (2021)

Level up for culture models - How 3D cell culture models benefit SARS-CoV-2 research
por: Häfner, Sophia Julia
Publicado: (2021)

How will previous infection or current vaccination strategies protect us from future SARS‐CoV‐2 variant infections?
por: Monteiro, Olivia
Publicado: (2022)

Innovative adjuvant augments potency of a SARS-CoV-2 subunit vaccine
por: Peng, Hua, et al.
Publicado: (2022)

SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies
por: Yang, Yang, et al.
Publicado: (2021)

TMPRSS2, a novel host-directed drug target against SARS-CoV-2
por: Keller, Christian, et al.
Publicado: (2022)

SARS-CoV-2 and the brain to be studied long-term
por: Lemprière, Sarah
Publicado: (2020)

Keeping track of the SARS-CoV-2 vaccine pipeline
por: Parker, Edward P. K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ulbr655kah84a5pbtq4n3lk057